Understanding medical care of transplant recipients through integrated registry and pharmacy claims data

Krista L. Lentine, Elizabeth Anyaegbu, Ana Gleisner, Mark A. Schnitzler, David Axelrod, Daniel C. Brennan, Vikas R. Dharnidharka, Elizabeth Abraham, Janet E. Tuttle-Newhall

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Background: Limited data exist on medication use aside from immunosuppression among large samples of kidney transplant recipients. Methods: We examined a novel database wherein Organ Procurement and Transplantation Network (OPTN) registry data were linked to records from a US pharmaceutical claims clearinghouse (2005-2010 claims) to examine pharmaceutical care at the first transplant anniversary (n = 16,157). We quantified the use of the following medication types within ±60 days of the first-year OPTN report according to estimated glomerular filtration rate (eGFR): antihypertensives, lipid-lowering, bone and mineral, and anemia treatments. Adjusted associations of medication use with eGFR and other clinical factors were quantified by multivariate logistic regression. Results: Requirements for multiple antihypertensive agents rose with lower eGFR, with β-blockers comprising the most commonly used antihypertensive agent. The adjusted likelihood of vitamin D (adjusted odds ratio (aOR) 2.07, 95% CI 1.19-3.59) and especially erythrocyte-stimulating agents (aOR 19.94, 95% CI 7.01-56.00) rose in a graded manner to peak with eGFR <15 versus >90, whereas statin use was most common with eGFR 30-59 ml/min/1.73 m2. Black race was independently associated with increased use of all classes of antihypertensives and vitamin D, but lower adjusted statin use. Rapamycin-based immunosuppression was associated with increased use of statins and erythrocyte-stimulating agents. Conclusions: Integrated registry and pharmacy fill data provide a novel tool for pharmacoepidemiologic investigations of delivered post-transplant care. Transplant recipients with reduced renal function have increased requirements for pharmaceutical care of comorbidities. Causes of racial variation in medication fills warrant further investigation.

Original languageEnglish (US)
Pages (from-to)420-429
Number of pages10
JournalAmerican Journal of Nephrology
Issue number5
StatePublished - Nov 2013


  • Antihypertensive agents
  • Comorbidity
  • Drug prescriptions
  • Glomerular filtration rate
  • Kidney transplantation
  • Pharmacy claims
  • Process assessment
  • Registries
  • Statins

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Understanding medical care of transplant recipients through integrated registry and pharmacy claims data'. Together they form a unique fingerprint.

Cite this